REFERENCES
1. Vaduganathan, M.; Mensah, G. A.; Turco, J. V.; Fuster, V.; Roth, G. A. The global burden of cardiovascular diseases and risk. J. Am. Coll. Cardiol. 2022, 80, 2361-71.
2. Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023. J. Am. Coll. Cardiol. 2025, 86, 2167-243.
4. Libby, P.; Ridker, P. M.; Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473, 317-25.
5. Ference, B. A.; Ginsberg, H. N.; Graham, I.; et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart. J. 2017, 38, 2459-72.
6. Ridker, P. M.; Everett, B. M.; Thuren, T.; et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017, 377, 1119-31.
7. Libby, P. Interleukin-1 beta as a target for atherosclerosis therapy. J. Am. Coll. Cardiol. 2017, 70, 2278-89.
8. Smith, B. R.; Edelman, E. R. Nanomedicines for cardiovascular disease. Nat. Cardiovasc. Res. 2023, 2, 351-67.
9. Ajoolabady, A.; Pratico, D.; Lin, L.; et al. Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell. Death. Dis. 2024, 15, 817.
10. Hu, B.; Boakye‐Yiadom, K. O.; Yu, W.; et al. Nanomedicine approaches for advanced diagnosis and treatment of atherosclerosis and related ischemic diseases. Adv. Healthc. Mater. 2020, 9, 2000336.
11. Zhang, J.; Tong, J.; Sun, Y.; et al. How advanced is nanomedicine to treat atherosclerosis? A comprehensive review of the literature. Int. J. Nanomedicine. 2026, 21, 563561.
12. Spadafora, L.; Quarta, R.; Martino, G.; et al. From mechanisms to management: tackling in-stent restenosis in the drug-eluting stent era. Curr. Cardiol. Rep. 2025, 27, 53.
13. Toldo, S.; Mezzaroma, E.; Buckley, L. F.; et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol. Ther. 2022, 236, 108053.
14. Tardif, J.; Kouz, S.; Waters, D. D.; et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 2019, 381, 2497-505.
15. Nidorf, S. M.; Fiolet, A. T. L.; Mosterd, A.; et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 2020, 383, 1838-47.
16. Ridker, P. M.; Everett, B. M.; Pradhan, A.; et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 2019, 380, 752-62.
17. Jolly, S. S.; d’Entremont, M. A.; Lee, S. F.; et al. Colchicine in acute myocardial infarction. N. Engl. J. Med. 2025, 392, 633-42.
18. Niu, Y.; Bai, N.; Ma, Y.; Zhong, P.; Shang, Y.; Wang, Z. Safety and efficacy of anti-inflammatory therapy in patients with coronary artery disease: a systematic review and meta-analysis. BMC. Cardiovasc. Disord. 2022, 22, 84.
19. Terkeltaub, R. A.; Furst, D. E.; Digiacinto, J. L.; Kook, K. A.; Davis, M. W. Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors. Arthritis. Rheum. 2011, 63, 2226-37.
20. Ley, K.; Laudanna, C.; Cybulsky, M. I.; Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7, 678-89.
21. Baumer, Y.; Irei, J.; Boisvert, W. A. Cholesterol crystals in the pathogenesis of atherosclerosis. Nat. Rev. Cardiol. 2025, 22, 315-32.
22. Tall, A. R.; Bornfeldt, K. E. Inflammasomes and atherosclerosis: a mixed picture. Circ. Res. 2023, 132, 1505-20.
23. Fidler, T. P.; Dunbar, A.; Kim, E.; et al. Suppression of IL-1β promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis. Nat. Cardiovasc. Res. 2024, 3, 60-75.
24. Fang, F.; Ni, Y.; Yu, H.; et al. Inflammatory endothelium-targeted and cathepsin responsive nanoparticles are effective against atherosclerosis. Theranostics 2022, 12, 4200-20.
25. Cochain, C.; Vafadarnejad, E.; Arampatzi, P.; et al. Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ. Res. 2018, 122, 1661-74.
26. Winkels, H.; Ehinger, E.; Vassallo, M.; et al. Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry. Circ. Res. 2018, 122, 1675-88.
27. Fernandez, D. M.; Rahman, A. H.; Fernandez, N. F.; et al. Single-cell immune landscape of human atherosclerotic plaques. Nat. Med. 2019, 25, 1576-88.
28. Lee, G. Y.; Kim, J.; Choi, K. Y.; et al. Hyaluronic acid nanoparticles for active targeting atherosclerosis. Biomaterials 2015, 53, 341-8.
29. Kojima, Y.; Weissman, I. L.; Leeper, N. J. The role of efferocytosis in atherosclerosis. Circulation 2017, 135, 476-89.
30. Jaiswal, S.; Natarajan, P.; Silver, A. J.; et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 2017, 377, 111-21.
31. Flores-Gomez, D.; Bekkering, S.; Netea, M. G.; Riksen, N. P. Trained immunity in atherosclerotic cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2021, 41, 62-9.
32. Bønaa, K. H.; Mannsverk, J.; Wiseth, R.; et al.; NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N. Engl. J. Med. 2016, 375, 1242-52.
33. Dangas, G. D.; Claessen, B. E.; Caixeta, A.; Sanidas, E. A.; Mintz, G. S.; Mehran, R. In-stent restenosis in the drug-eluting stent era. J. Am. Coll. Cardiol. 2010, 56, 1897-907.
34. Habib, A.; Finn, A. V. Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacol. Res. 2015, 93, 22-7.
35. Li, Z.; Wang, Q.; Jing, H.; Luo, X.; Du, L.; Duan, Y. cRGD peptide-modified nanocarriers for targeted delivery of angiogenesis inhibitors to attenuate advanced atherosclerosis. ACS. Appl. Nano. Mater. 2021, 4, 11554-62.
36. Liu, M.; Zhang, Y.; Ma, X.; et al. Synthesis and characterization of fucoidan‐chitosan nanoparticles targeting P‐selectin for effective atherosclerosis therapy. Oxid. Med. Cell. Longev. 2022, 2022, 8006642.
37. Xu, H.; She, P.; Ma, B.; Zhao, Z.; Li, G.; Wang, Y. ROS responsive nanoparticles loaded with lipid-specific AIEgen for atherosclerosis-targeted diagnosis and bifunctional therapy. Biomaterials 2022, 288, 121734.
38. Lin, Y.; Huang, C.; Hou, X.; Kah, J. C. Y.; Wang, J. Polydopamine and hyaluronic acid-coated dual-responsive silica nanoparticles for targeted atherosclerosis imaging and therapy. Nanoscale. Adv. 2025, 7, 7134-44.
39. Lin, Y.; Liu, J.; Chong, S. Y.; et al. Dual‐function nanoscale coordination polymer nanoparticles for targeted diagnosis and therapeutic delivery in atherosclerosis. Small 2024, 20, 2401659.
40. Wang, Y.; Zhang, K.; Li, T.; et al. Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications. Theranostics 2021, 11, 164-80.
41. Li, Y.; Yu, J.; Cheng, C.; et al. Platelet and erythrocyte membranes coassembled biomimetic nanoparticles for heart failure treatment. ACS. Nano. 2024, 18, 26614-30.
42. Bu, T.; Li, Z.; Hou, Y.; et al. Exosome-mediated delivery of inflammation-responsive Il-10 mRNA for controlled atherosclerosis treatment. Theranostics 2021, 11, 9988-10000.
43. Chen, S.; Zhang, W.; Tang, C.; et al. Macrophage membrane-functionalized manganese dioxide nanomedicine for synergistic treatment of atherosclerosis by mitigating inflammatory storms and promoting cholesterol efflux. J. Nanobiotechnol. 2024, 22, 664.
44. Mirshafiee, V.; Mahmoudi, M.; Lou, K.; Cheng, J.; Kraft, M. L. Protein corona significantly reduces active targeting yield. Chem. Commun. 2013, 49, 2557.
45. Zhang, H.; Zhao, S.; Zhang, Q.; et al. Surface charge‐determined protein coronas of nanoparticles control endothelial cells uptake under low magnitude shear stress. Exploration 2026, 6, 20240248.
46. Allijn, I. E.; Czarny, B. M.; Wang, X.; et al. Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. J. Control. Release. 2017, 247, 127-33.
47. Yang, C.; Yang, S.; Fang, S.; et al. PLGA nanoparticles enhanced cardio-protection of scutellarin and paeoniflorin against isoproterenol-induced myocardial ischemia in rats. Int. J. Pharm. 2023, 648, 123567.
48. Long, M.; Wang, L.; Kang, L.; et al. Prussian blue nanozyme featuring enhanced superoxide dismutase-like activity for myocardial ischemia reperfusion injury treatment. ACS. Nano. 2025, 19, 4561-81.
49. Li, T.; Yang, B.; Liu, X.; et al. Silica nanoparticles loaded with selenium quantum dots reduce myocardial ischemia-reperfusion injury by alleviating ferroptosis and mitochondrial dysfunction. Int. J. Nanomedicine. 2025, 20, 1843-64.
50. Zhang, H.; Jiang, H.; Xie, W.; et al. LNPs-mediated VEGF-C mRNA delivery promotes heart repair and attenuates inflammation by stimulating lymphangiogenesis post-myocardial infarction. Biomaterials 2025, 322, 123410.
51. Zhao, Y.; Shirasu, T.; Yodsanit, N.; et al. Biomimetic, ROS-detonable nanoclusters - a multimodal nanoplatform for anti-restenotic therapy. J. Control. Release. 2021, 338, 295-306.
52. Yin, R.; Yang, D.; Wu, J. Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics 2014, 4, 175-200.
53. Chu, T.; Li, Q.; Dai, C.; et al. A novel Nanocellulose-Gelatin-AS-IV external stent resists EndMT by activating autophagy to prevent restenosis of grafts. Bioact. Mater. 2023, 22, 466-81.
54. van der Valk, F. M.; van Wijk, D. F.; Lobatto, M. E.; et al. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine 2015, 11, 1039-46.
55. Liu, X.; Chen, B.; Chen, J.; et al. A cardiac‐targeted nanozyme interrupts the inflammation‐free radical cycle in myocardial infarction. Adv. Mater. 2024, 36, 2308477.
56. Chen, C.; Ma, J.; Duan, S.; et al. Mitigation of ischemia/reperfusion injury via selenium nanoparticles: suppression of STAT1 to inhibit cardiomyocyte oxidative stress and inflammation. Biomaterials 2025, 318, 123119.
57. Adkar, S. S.; Leeper, N. J. Efferocytosis in atherosclerosis. Nat. Rev. Cardiol. 2024, 21, 762-79.
58. Jansen, I.; Cahalane, R.; Hengst, R.; et al. The interplay of collagen, macrophages, and microcalcification in atherosclerotic plaque cap rupture mechanics. Basic. Res. Cardiol. 2024, 119, 193-213.
59. Vergallo, R.; Park, S. J.; Stone, G. W.; et al. Vulnerable or high-risk plaque: a JACC: Cardiovascular Imaging position statement. JACC. Cardiovasc. Imaging. 2025, 18, 709-40.
60. Mézquita, A. J. V.; Biavati, F.; Falk, V.; et al. Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group. Nat. Rev. Cardiol. 2023, 20, 696-714.
61. Cui, K.; Gao, X.; Wang, B.; et al. Epsin nanotherapy regulates cholesterol transport to fortify atheroma regression. Circ. Res. 2023, 132, e22-42.
62. He, Z.; Chen, W.; Hu, K.; et al. Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment. Nat. Nanotechnol. 2024, 19, 1386-98.
63. Xu, H.; She, P.; Zhao, Z.; Ma, B.; Li, G.; Wang, Y. Duplex responsive nanoplatform with cascade targeting for atherosclerosis photoacoustic diagnosis and multichannel combination therapy. Adv. Mater. 2023, 35, 2300439.
64. Hu, R.; Dai, C.; Dong, C.; et al. Living macrophage-delivered tetrapod PdH nanoenzyme for targeted atherosclerosis management by ROS scavenging, hydrogen anti-inflammation, and autophagy activation. ACS. Nano. 2022, 16, 15959-76.
65. Huang, H.; Wang, T.; Rousseau, J.; et al. Biomimetic nanodrug targets inflammation and suppresses YAP/TAZ to ameliorate atherosclerosis. Biomaterials 2024, 306, 122505.
66. Su, F.; Ye, W.; Shen, Y.; et al. Immuno‐nanocomplexes target heterogenous network of inflammation and immunity in myocardial infarction. Adv. Sci. 2024, 11, 2402267.
67. Xu, X.; Li, M.; Yu, F.; et al. Platelet membrane nanocarriers cascade targeting delivery system to improve myocardial remodeling post myocardial ischemia–reperfusion injury. Adv. Sci. 2024, 11, 2308727.
68. Halkos, M. E.; Zhao, Z. Q.; Kerendi, F.; et al. Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic. Res. Cardiol. 2008, 103, 525-36.
69. Schuleri, K. H.; Centola, M.; Evers, K. S.; et al. Cardiovascular magnetic resonance characterization of peri-infarct zone remodeling following myocardial infarction. J. Cardiovas. Magn. Reson. 2012, 14, 24.
70. Singh, S. P.; Kumari, M.; Kumari, S. I.; et al. Genotoxicity of nano- and micron-sized manganese oxide in rats after acute oral treatment. Mutat. Res. 2013, 754, 39-50.
71. Zhao, Y.; Qu, H.; Wang, Y.; Xiao, W.; Zhang, Y.; Shi, D. Small rodent models of atherosclerosis. Biomed. Pharmacother. 2020, 129, 110426.





